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Abstract
Dengue is an increasing medical problem in subtropical and tropical countries. The search for a safe and effective vaccine is complicated by
the fact that there are four types of dengue virus and that, if a vaccine is live attenuated, it should be proven not to cause the life-threatening
form of dengue, dengue haemorrhagic fever. So far one vaccine candidate, a four-valent chimeric vaccine constructed from a yellow fever
vaccine strain, has reached large clinical trials and has been shown to offer protection against dengue types 1, 3 and 54 but not against
dengue type 2. It is highly likely that an effective vaccine will be available in the next decade.
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Introduction
Dengue fever is a mosquito-borne ﬂavivirus infection. Four
serotypes of the virus have been identiﬁed and multiple
infections in the same individual are common because the
ﬁrst dengue infection is often in childhood. The two most
common vectors are Aedes aegypti and Aedes albopictus, which
are both day-biters and breed near human habitations. The
virus multiplies in the mosquitoes and there is no man-to--
man transmission. Clinically, dengue virus causes ﬂu-like
illness with fever as the main symptom and low mortality
rates. However, in about 5% of individuals who acquire a
second dengue infection, dengue haemorrhagic fever with
bleeding symptoms may occur and has a considerable
mortality.
Epidemiologically more than half of the world’s population
live in areas where there is a risk for dengue infections and
in the last 10 years there has been a rapid and marked
increase in the number of reported dengue outbreaks in
countries with tropical or subtropical climate (data from
Africa are still incomplete). According to WHO there are
50–100 million dengue cases per year globally, of which
500 000 are dengue haemorrhagic fever. The total annual
mortality is estimated to be about 22 000 cases. Most of the
dengue cases occur in urban areas; examples are Singapore
and Rio de Janeiro.
Vaccine Development
Presently there is no licensed dengue vaccine but there is a very
high level of interest in afﬂicted countries. Several factors explain
the slow rate of development of dengue vaccines. First, a vaccine
should be four-valent to cover all dengue types. Second, if the
vaccine is an attenuated one, the risk must be considered that
the vaccine could lead to dengue haemorrhagic fever in
recipients who have previously had dengue infections. Third,
dengue outbreaks are seasonal and the incidence varies from
year to year. Therefore studies to evaluate the efﬁcacy of a
vaccine candidate must be timed to a period with a high level of
infections. Fourth, as an immuno-local correlate of protection is
lacking, the efﬁcacy of a vaccine must be based on large phase III
trials. Fifth, the low mortality in dengue infections has, to some
degree, been a disincentive to develop vaccines, especially as it is
of major importance that an effective and safe dengue vaccine
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should be made available to the populations of endemic areas
rather than becoming a tourist vaccine or a vaccine for special
groups, e.g. military personnel.
Vaccine Candidates
The most common approach to development of a dengue
vaccine has been to use attenuated virus. Other approaches,
e.g. vaccines built on virus subunits, are in early clinical
development. The candidate that has proceeded farthest is the
Sanoﬁ Pasteur tetravalent dengue vaccine (Sanoﬁ, Lyon,
France) (1). It is a chimeric vaccine constructed from a strain
of yellow fever vaccine (YFV 17D) into which the prM genes of
the four dengue serotypes have been inserted. Preclinical
studies have shown that the vaccine stimulates human
dendritic cells, that it is not hepatotropic and that it is less
neurotropic than the YFV 17D vaccine. It has also been shown
to induce an immune response with production of neutralizing
antibodies to all four dengue serotypes (2). This dengue
vaccine has been evaluated in a large phase IIB trial in
Ratchaburi province in Thailand (2). The trial site had been
extensively evaluated before the study (3–5) and the study was
randomized, controlled and observer-blinded. More than 4000
schoolchildren aged 4–11 years were included and received
either the dengue vaccine or control (rabies vaccine for the
ﬁrst dose and then saline/placebo) at 0, 6 and 12 months. The
safety of the vaccine was shown to be excellent with no
differences between vaccine recipients and controls with
respect to side effects (2). Efﬁcacy results are summarized in
Table 1.
The overall protective efﬁcacy of the vaccine was only 30%.
This was due to the fact that during the study period the
predominant serotype in the study population was serotype 2
and protection against that serotype was much lower than
against the other three serotypes.
Discussion
The results of the Rachaburi trial with the Sanoﬁ tetravalent
vaccine show that we still do not have a dengue vaccine proven
in large studies to be safe and effective. However, large phase
III studies of the Sanoﬁ vaccine are ongoing in Australia, Asia
and Latin America and the manufacturer hopes to have it
licensed in 2015. Simultaneously, clinical trials have started of
other dengue vaccine candidates. According to the Dengue
Vaccine Initiative, a consortium including International Insti-
tute, Johns Hopkins University, the Sabin Foundation and
WHO, six vaccine candidates are in clinical trials (http://www.
denguevaccine.org/vaccine-development, Table 2). Of special
interest are the two products that are not live-attenuated
because they would not have a risk of dengue haemorrhagic
fever following vaccination.
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Person-years
at risk Cases
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GSK Live-attenuated Phase I
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